(1S,2S) -Bortezomib

(1S,2S) -Bortezomib is an enantiomer of Bortezomib. Bortezomib is a cell-permeable, reversible, and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki of 0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is an anti-cancer agent and the first therapeutic proteasome inhibitor to be used in humans[1][2][3].

Product Specifications

CAS Number

[1132709-14-8]

UNSPSC

12352005

Hazard Statement

H301, H315, H319, H331

Target

Apoptosis; Proteasome

Type

Reference compound

Related Pathways

Apoptosis; Metabolic Enzyme/Protease

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/1s-2s-bortezomib.html

Purity

97.0

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

OB([C@H](NC([C@@H](NC(C1=NC=CN=C1)=O)CC2=CC=CC=C2)=O)CC(C)C)O

Molecular Formula

C19H25BN4O4

Molecular Weight

384.24

Precautions

H301, H315, H319, H331

References & Citations

[1]Kamalzadeh Z, et al. Determination of Bortezomib in API Samples Using HPLC: Assessment of Enantiomeric and Diastereomeric Impurities. J Chromatogr Sci. 2017 Aug 1;55 (7) :697-705.|[2]Adams J, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999 Jun 1;59 (11) :2615-22.|[3]Shahshahan MA, et al. Potential usage of proteasome inhibitor bortezomib (Velcade, PS-341) in the treatment of metastaticmelanoma: basic and clinical aspects. Am J Cancer Res. 2011;1 (7) :913-24.